Cited by 172Protein Kinase Regulation and GTPase SignalingMechanisms of cancer metastasisCancer Mechanisms and Therapy

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

Open access

Switzer, C H, Cheng, R Y S, Vitek, T M, Christensen, D J, Wink, D A, Vitek, M P·2011·Oncogene

DOI 10.1038/onc.2010.622PMC PMC3107340

Open this paper in CoChat — free account

Abstract

The SET oncoprotein participates in cancer progression by affecting multiple cellular processes, inhibiting the tumor suppressor protein phosphatase 2A (PP2A), and inhibiting the metastasis suppressor nm23-H1. On the basis of these multiple activities, we hypothesized that targeted inhibition of SET would have multiple discrete and measurable effects on cancer cells. Here, the effects of inhibiting SET oncoprotein function on intracellular signaling and proliferation of human cancer cell lines was investigated. We observed the effects of COG112, a novel SET interacting peptide, on PP2A activity, Akt signaling, nm23-H1 activity and cellular migration/invasion in human U87 glioblastoma and MDA-MB-231 breast adenocarcinoma cancer cell lines. We found that COG112 interacted with SET protein and inhibited the association between SET and PP2A catalytic subunit (PP2A-c) and nm23-H1. The interaction between COG112 and SET caused PP2A phosphatase and nm23-H1 exonuclease activities to increase. COG112-mediated increases in PP2A activity resulted in the inhibition of Akt signaling and cellular proliferation. Additionally, COG112 inhibited SET association with Ras-related C(3) botulinum toxin substrate 1 (Rac1), leading to decreased cellular migration and invasion. COG112 treatment releases the SET-mediated inhibition of the tumor suppressor PP2A, as well as the metastasis suppressor nm23-H1. These results establish SET as a novel molecular target and that the inhibition of SET may have beneficial effects in cancer chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/onc.2010.622

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Rho Family GTPases Regulate p38 Mitogen-activated Protein Kinase through the Downstream Mediator Pak1
Zhang, S., Han, J., Sells, M. A., Chernoff, J., Knaus, U. G., Ulevitch, R. J., & Bokoch, G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.23934 · Cited by 726
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
Tumor Suppressor NM23-H1 Is a Granzyme A-Activated DNase during CTL-Mediated Apoptosis, and the Nucleosome Assembly Protein SET Is Its Inhibitor
Fan, Z., Beresford, P. J., Oh, D. Y., Zhang, D., & Lieberman, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00150-8 · Cited by 541
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Regulation of Histone Acetylation and Transcription by INHAT, a Human Cellular Complex Containing the Set Oncoprotein
Seo, S.-B., McNamara, P., Heo, S., Turner, A., Lane, W. S., & Chakravarti, D. (2001) · Cell · doi:10.1016/s0092-8674(01)00196-9 · Cited by 481
Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development
Rosengard, A. M., Krutzsch, H. C., Shearn, A., Biggs, J. R., Barker, E. A., Margulies, I., King, C. R., Liotta, L. A., & Steeg, P. S. (1989) · Nature · doi:10.1038/342177a0 · Cited by 481
The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A
Li, M., Makkinje, A., & Damuni, Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11059 · Cited by 479
Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene.
Lindern, M. V., van Baal, S., Wiegant, J. C. A. G., Raap, A. K., Hagemeijer, A., & Grosveld, G. C. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.8.3346 · Cited by 392
ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases
Olayioye, M. A., Beuvink, I., Horsch, K., Daly, J. M., & Hynes, N. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17209 · Cited by 373
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344

Show all 50 references

Sorted by citations

Protein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Protein Ser/ Thr phosphatases – the ugly ducklings of cell signalling
Brautigan, D. L. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08609.x · Cited by 231
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer
Janghorban, M., Farrell, A. S., Allen-Petersen, B. L., Pelz, C., Daniel, C. J., Oddo, J., Langer, E. M., Christensen, D. J., & Sears, R. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317630111 · Cited by 186
Self-citation
Reduced Insulin Production Relieves Endoplasmic Reticulum Stress and Induces β Cell Proliferation
Szabat, M., Page, M. M., Panzhinskiy, E., Skovsø, S., Mojibian, M., Fernandez-Tajes, J. J., Bruin, J. E., Bround, M. J., Lee, J. T. C., Xu, E. E., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.10.016 · Cited by 190
Selective PP2A enhancement through biased heterotrimer stabilization
Leonard, D., Huang, W., Izadmehr, S., O’Connor, C. M., Wiredja, D. D., Wang, Z., Zaware, N., Chen, Y., Schlatzer, D. M., Kiselar, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.038 · Cited by 176
“…yet underexplored strategy lies in the activation of phosphatases (Allen-Petersen et al., 2019; Cristóbal et al., 2015; Gutierrez et al., 2014; Ho et al., 2018; Kauko et al., 2018; Neviani et al., 2007; Rincón et al., 2015; Sangodkar et al., 2017; Switzer et al., 2011; Tohmé et al., 2019).”
Background
Diverse Functions of Ceramide in Cancer Cell Death and Proliferation
Saddoughi, S. A., & Öğretmen, B. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-394274-6.00002-9 · Cited by 186
Signaling and stress: The redox landscape in NOS2 biology
Thomas, D. D., Heinecke, J. L., Ridnour, L. A., Cheng, R. Y., Kesarwala, A. H., Switzer, C. H., McVicar, D. W., Roberts, D. D., Glynn, S., Fukuto, J. M., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.002 · Cited by 150
Self-citation
Structure, Regulation, and Pharmacological Modulation of PP2A Phosphatases
Lambrecht, C., Haesen, D., Sents, W., Ivanova, E., & Janssens, V. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-562-0_17 · Cited by 140
Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial
Chung, V. M., Mansfield, A. S., Braiteh, F., Richards, D., Durivage, H. J., Ungerleider, R. S., Johnson, F., & Kovach, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2299 · Cited by 129
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target
Christensen, D. J., Chen, Y., Oddo, J., Matta, K. M., Neil, J. E., Davis, E. D., Volkheimer, A. D., Lanasa, M. C., Friedman, D. R., Goodman, B. K., et al. (2011) · Blood · doi:10.1182/blood-2011-04-351072 · Cited by 133
Self-citation
Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
Agarwal, A., MacKenzie, R. J., Pippa, R., Eide, C. A., Oddo, J., Tyner, J. W., Sears, R. C., Vitek, M. P., Odero, M. D., Christensen, D. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2575 · Cited by 125
Self-citation
Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia
Cristóbal, I., García-Ortí, L., Cirauqui, C., Cortés-Lavaud, X., Garcı́a-Sánchez, A., Calasanz, M. J., & Odero, M. D. (2011) · Haematologica · doi:10.3324/haematol.2011.050542 · Cited by 126
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer
Farrell, A. S., Allen-Petersen, B., Daniel, C. J., Wang, X., Wang, Z., Rodriguez, S., Impey, S., Oddo, J., Vitek, M. P., Lopez, C., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0542 · Cited by 114
Self-citation
Challenges and Opportunities in the Development of Protein Phosphatase-Directed Therapeutics
Munter, S. D., Köhn, M., & Bollen, M. (2012) · ACS Chemical Biology · doi:10.1021/cb300597g · Cited by 120
Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration
Clark, A. R., & Ohlmeyer, M. H. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.016 · Cited by 108
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
Rincón, R., Cristóbal, I., Zazo, S., Arpí, O., Menéndez, S., Manso, R., Lluch, A. M., Eroles, P., Rovira, A., Albanell, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3012 · Cited by 101
Cracking the ANP32 whips: Important functions, unequal requirement, and hints at disease implications
Reilly, P. T., Yu, Y., Hamiche, A., & Wang, L. (2014) · BioEssays · doi:10.1002/bies.201400058 · Cited by 102
The Nuclear Oncogene SET Controls DNA Repair by KAP1 and HP1 Retention to Chromatin
Kalousi, A., Hoffbeck, A.-S., Selemenakis, P., Pinder, J. B., Savage, K. I., Khanna, K. K., Brino, L., Dellaire, G., Gorgoulis, V. G., & Soutoglou, E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.005 · Cited by 100
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer
Liu, H., Gu, Y., Wang, H., Yin, J., Zheng, G., Zhang, Z., Lu, M., Wang, C., & He, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.3818 · Cited by 96
MicroRNA-9 regulates steroid-resistant airway hyperresponsiveness by reducing protein phosphatase 2A activity
Li, J. J., Tay, H. L., Maltby, S., Xiang, Y., Eyers, F., Hatchwell, L., Zhou, H., Toop, H. D., Morris, J. C., Nair, P. K., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.044 · Cited by 94
PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.009 · Cited by 93
The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Janssens, V., & Rebollo, A. (2012) · Current Molecular Medicine · doi:10.2174/156652412799218930 · Cited by 95
Lipid rafts couple store-operated Ca 2+ entry to constitutive activation of PKB/Akt in a Ca 2+ /calmodulin-, Src- and PP2A-mediated pathway and promote melanoma tumor growth
Fedida-Metula, S., Feldman, B., Koshelev, V., Levin-Gromiko, U., Voronov, E., & Fishman, D. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs021 · Cited by 88
Circular MTHFD2L RNA-encoded CM-248aa inhibits gastric cancer progression by targeting the SET-PP2A interaction
Liu, H., Fang, D., Zhang, C., Zhao, Z., Liu, Y., Zhao, S., Zhang, N., & Xu, J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.04.013 · Cited by 82
Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer
Cristóbal, I., Rincón, R., Manso, R., Caramés, C., Zazo, S., Madoz-Gúrpide, J., Rojo, F., & García-Foncillas, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0724 · Cited by 78
Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models
Sobral, L. M., Sousa, L. O., Coletta, R. D., Cabral, H., Greene, L. J., Tajara, E. H., Gutkind, J. S., Curti, C., & Leopoldino, A. M. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-32 · Cited by 76
Differential Processing of let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET Oncoprotein
Bhutia, Y. D., Hung, S. W., Krentz, M., Patel, D., Lovin, D., Manoharan, R., Thomson, J. M., & Govindarajan, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053436 · Cited by 76
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer
Switzer, C. H., Glynn, S. A., Ridnour, L. A., Cheng, R. Y.-S., Vitek, M. P., Ambs, S., & Wink, D. A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.001 · Cited by 74
The basic biology of PP2A in hematologic cells and malignancies
Haesen, D., Sents, W., Lemaire, K., Hoorne, Y., & Janssens, V. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00347 · Cited by 73
Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity
Pippa, R., Dominguez, A., Christensen, D. J., Moreno–Miralles, I., Blanco‐Prieto, M. J., Vitek, M. P., & Odero, M. D. (2014) · Leukemia · doi:10.1038/leu.2014.141 · Cited by 73
Self-citation
Protein phosphatase 2A and tau: an orchestrated ‘Pas de Deux’
Taleski, G., & Sontag, E. (2017) · FEBS Letters · doi:10.1002/1873-3468.12907 · Cited by 71
Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer’s disease
Borin, M., Saraceno, C., Catania, M., Lorenzetto, E., Pontelli, V., Paterlini, A., Fostinelli, S., Avesani, A., Di Fede, G., Zanusso, G., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0567-4 · Cited by 68
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia
Arriazu, E., Pippa, R., & Odero, M. D. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00078 · Cited by 66
Viewing serine/threonine protein phosphatases through the eyes of drug designers
Zhang, M., Yogesha, S. D., Mayfield, J. E., Gill, G. N., & Zhang, Y. (2013) · FEBS Journal · doi:10.1111/febs.12481 · Cited by 66
Maintenance of higher H2O2 levels, and its mechanism of action to induce growth in breast cancer cells: Important roles of bioactive catalase and PP2A
Sen, S., Kawahara, B., & Chaudhuri, G. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.06.030 · Cited by 65
Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A
Yu, H.-C., Hung, M.-H., Chen, Y.-L., Chu, P.-Y., Wang, C. Y., Chao, T.-T., Liu, C.-Y., Shiau, C.-W., & Chen, K.-F. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.325 · Cited by 63
Circular RNA hsa_circ_0000673 promotes hepatocellular carcinoma malignance by decreasing miR-767-3p targeting SET
Jiang, W., Wen, D., Gong, L., Wang, Y., Liu, Z., & Yin, F. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.041 · Cited by 62
Using the MCoTI-II Cyclotide Scaffold To Design a Stable Cyclic Peptide Antagonist of SET, a Protein Overexpressed in Human Cancer
D’Souza, C., Henriques, S. T., Wang, C. K. L., Cheneval, O., Chan, L. Y., Bokil, N. J., Sweet, M. J., & Craik, D. J. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00529 · Cited by 61
PP2A-Mediated Anticancer Therapy
Chen, W., Wang, Z., Jiang, C., & Ding, Y. (2013) · Gastroenterology Research and Practice · doi:10.1155/2013/675429 · Cited by 59
SET protein accumulates in HNSCC and contributes to cell survival: Antioxidant defense, Akt phosphorylation and AVOs acidification
Leopoldino, A. M., SQUARIZE, C. H., Garcia, C. B., Almeida, L. O., Pestana, C. R., Sobral, L. M., Uyemura, S. A., Tajara, E. H., Gutkind, J. S., & Curti, C. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.05.014 · Cited by 56
27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer
Marwarha, G., Raza, S., Hammer, K. D. P., & Ghribi, O. (2017) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2017.05.012 · Cited by 59
Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation
Le Guelte, A., Galan-Moya, E.-M., Dwyer, J., Treps, L., Kettler, G., Hebda, J. K., Dubois, S., Auffray, C., Chneiweiss, H., Bidere, N., et al. (2012) · Journal of Cell Science · doi:10.1242/jcs.108282 · Cited by 80
Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression
Liu, C., Huang, T., Chen, Y., Chen, J.-L., Chu, P., Huang, C.-T., Wang, W.-L., Lau, K.-Y., Dai, M., Shiau, C., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.032 · Cited by 52
Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential
Hung, M.-H., Chen, Y.-L., Chu, P.-Y., Shih, C.-T., Yu, H.-C., Tai, W.-T., Shiau, C.-W., & Chen, K.-F. (2016) · Oncogene · doi:10.1038/onc.2016.21 · Cited by 48
The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers
Fujiki, H., Sueoka, E., Watanabe, T., & Suganuma, M. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2765-7 · Cited by 50
Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options
Grech, G., Baldacchino, S., Saliba, C., Grixti, M. P., Gauci, R., Magri, V. P., Fenech, A. G., & Scerri, C. A. (2016) · Tumor Biology · doi:10.1007/s13277-016-5145-4 · Cited by 48
Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A
Zonta, F., Pagano, M. A., Trentin, L., Tibaldi, E. V., Frezzato, F., Trimarco, V., Facco, M., Zagotto, G., Pavan, V., Ribaudo, G., et al. (2015) · Blood · doi:10.1182/blood-2014-12-619155 · Cited by 47
The Rac1 hypervariable region in targeting and signaling
Lam, B. D., & Hordijk, P. L. (2013) · Small GTPases · doi:10.4161/sgtp.23310 · Cited by 48
Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway
Zhang, W., Cai, J., Chen, S., Zheng, X., Hu, S., Dong, W., Lü, J., Xing, J., & Dong, Y. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3468 · Cited by 44
PP2A Inhibits Cervical Cancer Cell Migration by Dephosphorylation of p-JNK, p-p38 and the p-ERK/MAPK Signaling Pathway
Zheng, H., Shen, F., Tong, Y., & Li, Y. (2018) · Current Medical Science · doi:10.1007/s11596-018-1854-9 · Cited by 44
Mitochondrial-associated nitric oxide synthase activity inhibits cytochrome c oxidase: Implications for breast Cancer
Sen, S., Kawahara, B., & Chaudhuri, G. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.545 · Cited by 42
A comprehensive and perspective view of oncoprotein SET in cancer
Bayarkhangai, B., Noureldin, S., Yu, L., Zhao, N., Gu, Y., Xu, H., & Guo, C. (2018) · Cancer Medicine · doi:10.1002/cam4.1526 · Cited by 40
Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer
Zhang, Q., Fan, Z., Zhang, L., You, Q., & Wang, L. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00631 · Cited by 38
Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis
Hu, X., Garcia, C., Fazli, L., Gleave, M. E., Vitek, M. P., Jansen, M., Christensen, D. J., & Mulholland, D. J. (2015) · Scientific Reports · doi:10.1038/srep15182 · Cited by 37
Self-citation
The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias
Pippa, R., & Odero, M. D. (2020) · Cells · doi:10.3390/cells9030544 · Cited by 38
SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell
Liu, H., Gu, Y., Yin, J., Zheng, G., Wang, C., Zhang, Z., Deng, M., Liu, J., Jia, X., & He, Z. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.08.010 · Cited by 36
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A
Hung, M., Wang, C., Chen, Y., Chu, P., Hsiao, Y., Tai, W., Chao, T.-T., Yu, H.-C., Shiau, C., & Chen, K. (2015) · Oncotarget · doi:10.18632/oncotarget.6313 · Cited by 35
Endogenous inhibitor proteins that connect Ser/Thr kinases and phosphatases in cell signaling
Eto, M., & Brautigan, D. L. (2012) · IUBMB Life · doi:10.1002/iub.1067 · Cited by 36
Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia
Richard, N. P., Pippa, R., Cleary, M. M., Puri, A., Tibbitts, D., Mahmood, S., Christensen, D. J., Jeng, S., McWeeney, S. K., Look, A. T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12394 · Cited by 33
Self-citation
The interaction of SET and protein phosphatase 2A as target for cancer therapy
Dacol, E. C., Wang, S., Chen, Y., & Lepique, A. P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188578 · Cited by 35
Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia
Wang, S., Xie, W., Wang, D., Peng, Z., Zheng, Y., Liu, N., Dai, W., Wang, Y., Wang, Z., Yang, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3665 · Cited by 32
Cytoplasmic targeting of the proto‐oncogene SET promotes cell spreading and migration
Lam, B. D., Anthony, E. C., & Hordijk, P. L. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.11.013 · Cited by 30
Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia
Ramaswamy, K., Spitzer, B. G., & Kentsis, A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00016 · Cited by 30
Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review
Cristóbal, I., Madoz‐Gúrpide, J., Manso, R., Gónzález-Alonso, P., Rojo, F., & García‐Foncillas, J. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1162774 · Cited by 29
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia
Rocca, S., Carrà, G., Poggio, P., Morotti, A., & Brancaccio, M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0774-4 · Cited by 28
Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer
Hung, M., & Chen, K. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1336226 · Cited by 29
Inhibition of the PP2A activity by the histone chaperone ANP32B is long-range allosterically regulated by respiratory cytochrome c
Rivero-Rodríguez, F., Dı́az-Quintana, A., Velázquez‐Cruz, A., González‐Arzola, K., Gavilán, M. P., Velázquez‐Campoy, A., Rios, R. M., la Rosa, M. Á. D., & Díaz‐Moreno, I. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101967 · Cited by 27
A Vesicular Stomatitis Virus‐Inspired DNA Nanocomplex for Ovarian Cancer Therapy
Zhao, W., Yang, Y., Song, L., Kang, T., Du, T., Wu, Y., Xiong, M., Luo, L., Long, J., Men, K., et al. (2017) · Advanced Science · doi:10.1002/advs.201700263 · Cited by 25
PP2A and Its Inhibitors in Helper T-Cell Differentiation and Autoimmunity
Khan, M. M., Ullah, U., Khan, M. H., & Lahesmaa, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786857 · Cited by 26
Identification of miR-145 targets through an integrated omics analysis
Huang, T., Renuse, S., Pinto, S. M., Kumar, P., Yang, Y., Chaerkady, R., Godsey, B., Mendell, J. T., Halushka, M. K., Civin, C. I., et al. (2014) · Molecular BioSystems · doi:10.1039/c4mb00585f · Cited by 25
3-Bromopyruvate treatment induces alterations of metabolic and stress-related pathways in glioblastoma cells
Chiasserini, D., Davidescu, M., Orvietani, P. L., Susta, F., Macchioni, L., Petricciuolo, M., Castigli, E., Roberti, R., Binaglia, L., & Corazzi, L. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.11.013 · Cited by 24
Cellular inhibitors of Protein Phosphatase PP2A in cancer.
Haesen, D., Sents, W., Ivanova, E., Lambrecht, C., & Janssens, V. (2012) · Lirias · Cited by 24
Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer
Cristóbal, I., Torrejón, B., Rubio, J., Santos, A., Pedregal, M., Caramés, C., Zazo, S., Luque, M., Sanz-Álvarez, M., Madoz‐Gúrpide, J., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030346 · Cited by 23
Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment
Mukhopadhyay, A., Tabanor, K., Chaguturu, R., & Aldrich, J. V. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.25943 · Cited by 23
Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS)
Jiang, S., Xu, S., Chen, H., Liu, X., Tang, Z., Cui, Y., & Liu, J. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.11.010 · Cited by 23
Protocadherin 7 is overexpressed in castration resistant prostate cancer and promotes aberrant MEK and AKT signaling
Shishodia, G., Koul, S., & Koul, H. K. (2019) · The Prostate · doi:10.1002/pros.23898 · Cited by 22
Vascular smooth muscle RhoA counteracts abdominal aortic aneurysm formation by modulating MAP4K4 activity
Molla, M. R., Shimizu, A., Komeno, M., Rahman, N. I. A., Soh, J. E. C., Nguyen, L. K. C., Khan, M. R., Tesega, W. W., Chen, S., Pang, X., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04042-z · Cited by 22
Targeting phosphatases: From molecule design to clinical trials
Guo, M., Li, Z., Gu, M., Gu, J., You, Q., & Wang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116031 · Cited by 23
Proteomics Identified Overexpression of SET Oncogene Product and Possible Therapeutic Utility of Protein Phosphatase 2A in Alveolar Soft Part Sarcoma
Kubota, D., Yoshida, A., Kawai, A., & Kondo, T. (2014) · Journal of Proteome Research · doi:10.1021/pr400929h · Cited by 22
Functional modulation of the metastatic suppressor Nm23-H1 by oncogenic viruses
Saha, A., & Robertson, E. S. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.007 · Cited by 22
Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer
Cristóbal, I., Caramés, C., Rincón, R., Manso, R., Madoz‐Gúrpide, J., Torrejón, B., Gónzález-Alonso, P., Rojo, F., & García‐Foncillas, J. (2016) · Oncotarget · doi:10.18632/oncotarget.11174 · Cited by 22
Exploring and exploiting plant cyclic peptides for drug discovery and development
Zhang, J., Yuan, J., Li, Z., Fu, C., Xu, M., Yang, J., Jiang, X. M., Zhou, B., Ye, X., & Xu, C. (2021) · Medicinal Research Reviews · doi:10.1002/med.21792 · Cited by 21
A Potential Therapeutic Application of SET/I2PP2A Inhibitor OP449 for Canine T-cell Lymphoma
Fujiwara, N., Kawasaki, H., Yabe, R., Christensen, D. J., Vitek, M. P., Mizuno, T., Sato, K., & Ohama, T. (2012) · Journal of Veterinary Medical Science · doi:10.1292/jvms.12-0366 · Cited by 23
Self-citation
Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma
Bownes, L. V., Marayati, R., Quinn, C. H., Beierle, A. M., Hutchins, S. C., Julson, J. R., Erwin, M. H., Stewart, J. E., Mroczek‐Musulman, E., Ohlmeyer, M. H. J., et al. (2022) · Cancers · doi:10.3390/cancers14081952 · Cited by 21
CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling
Khan, M. M., Ullah, U., Khan, M. H., Kong, L., Moulder, R., Välikangas, T., Bhosale, S. D., Komsi, E., Rasool, O., Chen, Z. J., et al. (2020) · iScience · doi:10.1016/j.isci.2020.100947 · Cited by 19
Stable SET knockdown in breast cell carcinoma inhibits cell migration and invasion
Li, J., Yang, X., Ren, X., Meng, X.-J., Huang, H., Zhao, Q.-H., Yuan, J., Hong, W., Xia, B., Huang, X., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.013 · Cited by 19
Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications
Tian, L., Zhang, X., Haesen, D., Bravo, J., Fominaya, J. M., Choquet, S., Zini, J. M., Loisel, S., Waelkens, E., Janssens, V., et al. (2017) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-017-9633-1 · Cited by 20
Bifunctional Therapeutic Peptides for Targeting Malignant B Cells and Hepatocytes: Proof of Concept in Chronic Lymphocytic Leukemia
Simón‐Gracia, L., Savier, É., Parizot, C., Brossas, J. Y., Loisel, S., Teesalu, T., Conti, F., Charlotte, F., Scatton, O., Aoudjehane, L., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000131 · Cited by 18
SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia
Brander, D. M., Friedman, D. R., Volkheimer, A. D., Christensen, D. J., Rassenti, L. Z., Kipps, T. J., Guadalupe, E., Chen, Y., Zhang, D., Wang, X., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15677 · Cited by 18
Self-citation
Proteomic Analysis on Anti-Proliferative and Apoptosis Effects of Curcumin Analog, 1,5-bis(4-Hydroxy-3-Methyoxyphenyl)-1,4-Pentadiene-3-One-Treated Human Glioblastoma and Neuroblastoma Cells
Lee, Y. Q., Rajadurai, P., Abas, F., Othman, I., & Naidu, R. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.645856 · Cited by 18
SET protein overexpression contributes to paclitaxel resistance in MCF-7/S cells through PI3K/Akt pathway
Zhang, W., Zheng, X., Meng, T., You, H., Dong, Y., Xing, J., & Chen, S. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1245307 · Cited by 17
Identification and characterization of novel enhanced cell penetrating peptides for anti-cancer cargo delivery
Zhang, X., Brossas, J. Y., Parizot, C., Zini, J. M., & Rebollo, A. (2017) · Oncotarget · doi:10.18632/oncotarget.23179 · Cited by 19
Analysis of nucleo‐cytoplasmic shuttling of the proto‐oncogene SET/I2PP2A
Lam, B. D., Anthony, E. C., & Hordijk, P. L. (2011) · Cytometry Part A · doi:10.1002/cyto.a.21153 · Cited by 17
Oncoprotein SET-associated transcription factor ZBTB11 triggers lung cancer metastasis
Xu, W., Yao, H., Wu, Z., Yan, X., Jiao, Z., Liu, Y., Zhang, M., & Wang, D. (2024) · Nature Communications · doi:10.1038/s41467-024-45585-5 · Cited by 18
Subcellular Proteomics Reveals a Role for Nucleo-cytoplasmic Trafficking at the DNA Replication Origin Activation Checkpoint
Mulvey, C. M., Tudzarova, S., Crawford, M., Williams, G. H., Stoeber, K., & Godovac‐Zimmermann, J. (2013) · Journal of Proteome Research · doi:10.1021/pr3010919 · Cited by 16
OP449 inhibits breast cancer growth without adverse metabolic effects
Shlomai, G., Zelenko, Z., Antoniou, I. M., Stasinopoulos, M., Tobin‐Hess, A., Vitek, M. P., LeRoith, D., & Gallagher, E. J. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0077 · Cited by 16
Self-citation
PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer
Zhao, H., Li, D., Zhang, B., Qi, Y., Diao, Y.-P., Zhen, Y., & Shu, X. H. (2017) · Molecules · doi:10.3390/molecules22122277 · Cited by 16
Human apolipoprotein E genotypes differentially modify house dust mite-induced airway disease in mice
Yao, X., Dai, C., Fredriksson, K., Lam, J. Y., Gao, M., Keeran, K. J., Nugent, G. Z., Qu, X., Yu, Z., Jeffries, N. O., et al. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00110.2011 · Cited by 14
SET protein accumulation prevents cell death in head and neck squamous cell carcinoma through regulation of redox state and autophagy
Ouchida, A. T., Uyemura, V. T., Queiroz, A. L., Brauer, V. S., Neto, M. P. C., Sousa, L. O., Uyemura, S. A., Curti, C., & Leopoldino, A. M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.01.005 · Cited by 15

Authors: Switzer, C. H., Cheng, R. Y. S., Vitek, T. M., Christensen, D. J., Wink, D. A., & Vitek, M. P.
Affiliations: National Institutes of Health (US)
Cognosci (United States) (US)
Duke Medical Center (US)
Corresponding author: Wink, D A
Vitek, M P
ORCID: Switzer, C H
Cheng, R Y S
Christensen, D J
Wink, D A
Vitek, M P
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2011-02-07
Volume: 30
Issue: 22
Pages: 2504-2513
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/onc.2010.622
PMC: PMC3107340
OpenAlex: W2021359328
Cited by: 171
References: 50
Citations by year: 2026: 2 · 2025: 6 · 2024: 3 · 2023: 11 · 2022: 12 · 2021: 12 · 2020: 9 · 2019: 10 · 2018: 11 · 2017: 16 · 2016: 15 · 2015: 14 · 2014: 15 · 2013: 14 · 2012: 15
FWCI: 6.49
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (ZIASC007281, ZIABC010899)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: protein phosphatase 2A, nm23-H1, Akt signaling, cell proliferation, cell migration and invasion, Rac1, glioblastoma, breast adenocarcinoma, metastasis suppressor, tumor suppressor gene reactivation, cancer therapy targets
MeSH terms: Antineoplastic Agents, Cell Movement, DNA-Binding Proteins, Humans, Neoplasms, Peptides, Transcription Factors, Signal Transduction, rac1 GTP-Binding Protein, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt, NM23 Nucleoside Diphosphate Kinases, Histone Chaperones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks